Furthermore, B‐lymphocyte antigen CD19, which is expressed by B cells prior to terminal differentiation into plasma cells, is associated with the enhancement of myeloma's tumor‐propagating and drug‐resistance properties. The gene discussed is CD19; the disease is plasma cell myeloma.